Bcr Abl1 Test

The BCR-ABL1 test is a diagnostic tool used to detect a specific genetic abnormality in leukemia, known as the Philadelphia chromosome. This chromosome results from a translocation between the BCR and ABL1 genes, leading to the production of a fusion gene. The test helps identify this abnormality, which is most commonly associated with chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL).

The BCR-ABL1 test is typically done using a blood or bone marrow sample. The sample is sent to a specialized laboratory where genetic material is analyzed. Two common methods for this analysis are PCR (polymerase chain reaction) and FISH (fluorescence in situ hybridization). These tests detect the BCR-ABL1 fusion gene's presence and quantify the level of the fusion gene, known as the BCR-ABL1 transcript. The results are reported as a percentage, known as the "BCR-ABL1/ABL1 ratio," which helps gauge the disease burden.

BCR-ABL1 test results indicate the presence and quantity of the BCR-ABL1 fusion gene, expressed as a percentage (BCR-ABL1/ABL1 ratio). A higher percentage suggests a higher disease burden. Results help classify the stage of leukemia, monitor treatment response, and adjust treatment plans accordingly. A deep molecular response (low percentage) is the goal of therapy, indicating a successful response to treatment and a better prognosis.

BCR-ABL1 test results guide treatment choices, especially in CML. They inform the use of tyrosine kinase inhibitors (TKIs), which are targeted therapies designed to inhibit the activity of the BCR-ABL1 fusion protein. The specific TKI and its dosage may vary based on the BCR-ABL1 test results and the stage of the disease. Regular testing helps healthcare providers determine if the treatment is effective or if adjustments are needed.